Skip to main content
PMC home page
Public Health Reports logoLink to Public Health Reports
. 2005 May-Jun;120(3):230–239. doi: 10.1177/003335490512000304

A two-stage sampling method for clinical surveillance of individuals in care for HIV infection in the United States.

Patrick S Sullivan 1, John M Karon 1, Faye E Malitz 1, Stephanie Broyles 1, Eve D Mokotoff 1, Susan E Buskin 1, Patricia L Fleming 1
PMCID: PMC1497713  PMID: 16134562

Abstract

OBJECTIVES: The goals of this study were two-fold: (1) to describe methods for drawing a population-based sample of individuals in care for HIV infection and (2) to compare data from the sample with data from existing surveillance systems that describe care for HIV. METHODS: The authors implemented a two-stage sampling method, using local HIV/AIDS surveillance data as a sampling frame of HIV care providers in three states. At selected providers, medical records of a random sample of patients were abstracted. RESULTS: The medical records of a number of patients, ranging from 253 to 374 individuals per state, were abstracted. The demographics of sampled individuals and of individuals reported to the local HIV/AIDS surveillance program were similar; however, differences existed in the proportion of individuals receiving HIV care consistent with treatment guidelines between the sample and a contemporary facility-based supplemental surveillance project. The median design effect for outcomes collected in the sample was 1.8 (range=0.5-29.6). CONCLUSIONS: This survey method is feasible for collecting population-based data on patients in care for HIV. Sample size and some design elements should be changed in future studies to increase precision of estimates and usefulness of data for local planning and evaluation.

Full Text

The Full Text of this article is available as a PDF (107.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bozzette S. A., Berry S. H., Duan N., Frankel M. R., Leibowitz A. A., Lefkowitz D., Emmons C. A., Senterfitt J. W., Berk M. L., Morton S. C. The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium. N Engl J Med. 1998 Dec 24;339(26):1897–1904. doi: 10.1056/NEJM199812243392606. [DOI] [PubMed] [Google Scholar]
  2. Dworkin M. S., Hanson D. L., Kaplan J. E., Jones J. L., Ward J. W. Risk for preventable opportunistic infections in persons with AIDS after antiretroviral therapy increases CD4+ T lymphocyte counts above prophylaxis thresholds. J Infect Dis. 2000 Jul 14;182(2):611–615. doi: 10.1086/315734. [DOI] [PubMed] [Google Scholar]
  3. Farizo K. M., Buehler J. W., Chamberland M. E., Whyte B. M., Froelicher E. S., Hopkins S. G., Reed C. M., Mokotoff E. D., Cohn D. L., Troxler S. Spectrum of disease in persons with human immunodeficiency virus infection in the United States. JAMA. 1992 Apr 1;267(13):1798–1805. [PubMed] [Google Scholar]
  4. Frankel M. R., Shapiro M. F., Duan N., Morton S. C., Berry S. H., Brown J. A., Burnam M. A., Cohn S. E., Goldman D. P., McCaffrey D. F. National probability samples in studies of low-prevalence diseases. Part II: Designing and implementing the HIV cost and services utilization study sample. Health Serv Res. 1999 Dec;34(5 Pt 1):969–992. [PMC free article] [PubMed] [Google Scholar]
  5. Hsu L. C., Vittinghoff E., Katz M. H., Schwarcz S. K. Predictors of use of highly active antiretroviral therapy (HAART) among persons with AIDS in San Francisco, 1996-1999. J Acquir Immune Defic Syndr. 2001 Dec 1;28(4):345–350. doi: 10.1097/00126334-200112010-00007. [DOI] [PubMed] [Google Scholar]
  6. Jones J. L., Hanson D. L., Dworkin M. S., Alderton D. L., Fleming P. L., Kaplan J. E., Ward J. Surveillance for AIDS-defining opportunistic illnesses, 1992-1997. MMWR CDC Surveill Summ. 1999 Apr 16;48(2):1–22. [PubMed] [Google Scholar]
  7. Kaplan J. E., Hanson D. L., Navin T. R., Jones J. L. Risk factors for primary Pneumocystis carinii pneumonia in human immunodeficiency virus-infected adolescents and adults in the United States: reassessment of indications for chemoprophylaxis. J Infect Dis. 1998 Oct;178(4):1126–1132. doi: 10.1086/515658. [DOI] [PubMed] [Google Scholar]
  8. Klevens R. M., Fleming P. L., Li J., Gaines C. G., Gallagher K., Schwarcz S., Karon J. M., Ward J. W. The completeness, validity, and timeliness of AIDS surveillance data. Ann Epidemiol. 2001 Oct;11(7):443–449. doi: 10.1016/s1047-2797(01)00256-3. [DOI] [PubMed] [Google Scholar]
  9. Lee L. M., Karon J. M., Selik R., Neal J. J., Fleming P. L. Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984-1997. JAMA. 2001 Mar 14;285(10):1308–1315. doi: 10.1001/jama.285.10.1308. [DOI] [PubMed] [Google Scholar]
  10. McNaghten A. D., Hanson D. L., Jones J. L., Dworkin M. S., Ward J. W. Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis. Adult/Adolescent Spectrum of Disease Group. AIDS. 1999 Sep 10;13(13):1687–1695. doi: 10.1097/00002030-199909100-00012. [DOI] [PubMed] [Google Scholar]
  11. Moore R. D., Stanton D., Gopalan R., Chaisson R. E. Racial differences in the use of drug therapy for HIV disease in an urban community. N Engl J Med. 1994 Mar 17;330(11):763–768. doi: 10.1056/NEJM199403173301107. [DOI] [PubMed] [Google Scholar]
  12. Nakashima Allyn K., Fleming Patricia L. HIV/AIDS surveillance in the United States, 1981-2001. J Acquir Immune Defic Syndr. 2003 Feb;32 (Suppl 1):S68–S85. [PubMed] [Google Scholar]
  13. Shapiro M. F., Berk M. L., Berry S. H., Emmons C. A., Athey L. A., Hsia D. C., Leibowitz A. A., Maida C. A., Marcus M., Perlman J. F. National probability samples in studies of low-prevalence diseases. Part I: Perspectives and lessons from the HIV cost and services utilization study. Health Serv Res. 1999 Dec;34(5 Pt 1):951–968. [PMC free article] [PubMed] [Google Scholar]

Articles from Public Health Reports are provided here courtesy of SAGE Publications

RESOURCES